Cytonus Therapeutics Announces Publication in Nature Biomedical Engineering of Preclinical Results to Support Disease-Specific Drug-Delivery Capabilities of their Novel Cargocyte™ Platform

SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc., a US-based biotechnology company developing an innovative drug-delivery platform technology called Cargocytes, today announced the publication of a peer reviewed research paper in the high impact journal, Nature Biomedical Engineering. The study showed that Cargocytes, which are genetically engineered with a GPS-like cellular navigation system, can selectively target disease tissue within hours after being administered and produce bioactive
Click here to view original post